This compound is an active pharmaceutical ingredient impurity, characterized as a benzimidazole derivative with sulfoxide and pyridine substituents. It is a high-molecular-weight, lipophilic, and non-basic compound containing multiple ether linkages and aromatic rings.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 935260-92-7
Linzagolix
pharmaceutical raw material
Ceftolozane sulfate
pharmaceutical raw material
PCI-32765 (Racemate)
pharmaceutical raw material
Ibrutinib
pharmaceutical raw material
5-Methoxy-1-((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
pharmaceutical intermediate
1-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methyl]-2-[[4-(3-methoxypropoxy)-3-methyl-2-pyridinyl]methylsulfinyl]benzimidazole
GPEBYGLKBPIFHI-UHFFFAOYSA-N
CC1=C(C=CN=C1CN2C3=CC=CC=C3N=C2S(=O)CC4=NC=CC(=C4C)OCCCOC)OCCCOC